← Back to Analyst Consensus 
TLX N/A
Telix Pharmaceuticals Ltd
Current Price —
Implied Upside —
Analysts 0
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 25, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 23, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 14, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 20, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jul 7, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jul 7, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 6, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Apr 13, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Apr 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 7, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Apr 7, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 24, 2026 | Citigroup | maintain | Buy → Buy | $22.5 | 54% |
| Jan 21, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Dec 22, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Sep 23, 2025 | UBS | maintain | Buy → Buy | $20 | 54% |
| Sep 18, 2025 | Citigroup | initiate | — → Buy | $22 | 54% |
| Sep 10, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Aug 28, 2025 | JP Morgan | downgrade | Overweight → Neutral | $0 | 54% |
| Aug 28, 2025 | Wedbush | reiterate | Outperform → Outperform | $22 | 58% |
| Jul 3, 2025 | HC Wainwright & Co. | initiate | — → Buy | $23 | 44% |
| Jun 12, 2025 | Wedbush | reiterate | Outperform → Outperform | $22 | 58% |
| Jun 5, 2025 | Wedbush | initiate | — → Outperform | $22 | 58% |
| Jan 27, 2025 | UBS | maintain | Buy → Buy | $22 | 54% |
| Nov 15, 2024 | UBS | initiate | — → Buy | $21 | 54% |
Price Target Trend
Jun 7, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days